Source of fibrinogen, factor 8, and some cold insoluble proteins
Indications: hypofibrinogenemia
References
Corwin HL, Gettinger A, Rodriquez RM, et al. Efficacy of recombinant human erythropoietin in the critically-ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27: 2346-2350
Goodnough LT, Briecher ME, Kanter MH, et al. Transfusion medicine: first of two parts: Blood transfusion. N Engl J Med 1999; 340:438-447
Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417
Klein HG. Immunomodulatory aspects of transfusion; a once and future risk? Anesthesiology 1999; 91:861-865
Jensen LS. Benefits of leukocyte-reduced blood transfusions in surgical patients. Curr Opin Hemat 1998; 5:376-380
Goodnough LT, Briecher ME, Kanter MH, et al. Transfusion medicine: first of two parts: Blood transfusion. N Engl J Med 1999; 340:438-447
Vincent J, Baron J, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507.
Corwin H, Gerringer A, Rodriquez T, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double blind placebo controlled trial. Crit Care Med 1999; 27:2346-2350.
Nuttall G. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiol 2000; 92:674-682.
Bailie G, Johnson C, Mason N. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 2000; 35:1-12
